MORE VIDEOS
Explore more

Leukemia - Acute Myeloid - AML

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia administrator 1 Views • 2 years ago

Speakers: Prof. Arnold Ganser, Dr. Daver Naval
Acute Myeloid Leukemia (AML): Finally Making Progress? J. Zeidner - 20180523
Acute Myeloid Leukemia (AML): Finally Making Progress? J. Zeidner - 20180523 administrator 4 Views • 2 years ago

Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy that affects approximately 20,000 patients each year in the United States. Management of AML has changed little over the last several decades and outcomes remain unsatisfactory. However, recent drug discoveries and approvals show tremendous promise. This presentation will review the current treatment armamentarium of AML highlighting novel concepts and investigational agents in development.
Talking Post-Transplant Acute Myeloid Leukemia - Improving Outcomes after Relapse
Talking Post-Transplant Acute Myeloid Leukemia - Improving Outcomes after Relapse administrator 2 Views • 2 years ago

October 25, 2022 Archive

A CME Webcast Series

AMA Activity

The Talking Post-Transplant Acute Myeloid Leukemia (AML) webcast series will provide recent updates to improve outcomes in post-transplantation relapse in AML.

This webcast series, led by expert faculty, will provide guidance and practical strategies to safely implement recent progress in addressing post-transplantation relapse in AML. Through patient cases and scenarios, faculty presenters will guide the integration of new evidence into clinical treatment paradigms of AML in the post-transplantation setting. The activity will be supported by downloadable slides that have the key discussion/teaching points.

FACULTY
Keith Pratz, MD
Director of Leukemia
University of Pennsylvania

Gail Roboz, MD
Professor of Medicine
Weill Cornell Medicine
Director, Leukemia Program
Weill Cornell Medicine and
New York Presbyterian Hospital

Review the activity at https://bit.ly/3Up941S and claim AMA credit/contact hour after completion of a brief pretest and posttest/evaluation.

This activity is provided in collaboration with The University of Cincinnati and Practice Point Communications

Supported by independent educational grants from
Astellas and Bristol Myers Squibb

ACUTE MYELOID LEUKAEMIA II HEMATOLOGY II ROBBINS 10TH E II PATHOLOGY LECTURES II @DrJIBRANAHMED
ACUTE MYELOID LEUKAEMIA II HEMATOLOGY II ROBBINS 10TH E II PATHOLOGY LECTURES II @DrJIBRANAHMED administrator 3 Views • 2 years ago

Join this channel to get access to perks:
https://www.youtube.com/channe....l/UC4q9_TtRnc-Z2O82v

WELCOME BACK TO ANOTHER SWEET DOSE OF PATHOLOGY!!

BUY ROBBINS SOUTH EAST ASIA PATHOLOGIC BASIS OF DISEASE 10TH EDITION TODAY
https://amzn.to/3mrvcqW

BUY ROBBINS BASIC FIRST SOUTH EAST ASIA EDITION
https://amzn.to/2JEIvpu

FOR PRIVATE CLASSES PLEASE CONTACT ME AT
EMAIL: ahmedjibran90@gmail.com
Watsapp no. +91-9073120651

00:00 INTRO
00:12 TRAILER 1
01:24 TRAILER 2
01:55 MYELOID NEOPLASM KEY REVISION CONCEPTS
09:27 MAJOR CATEGORIES OF MYELOID NEOPLASM
18:26 FAB CLASSIFICATION OF AML(OLD)
28:19 LATEST WHO CLASSIFICATION OF AML
35:49 PATHOGENESIS OF AML
41:42 MORPHOLOGY OF AML
51:01 FAB M1
52:34 FAB M2
55:12 FAB M5
57:50 IPT OF AML
58:50 CLINICAL FEATURES
1:03:45 THE END

FOLLOW MY INSTAGRAM ACCOUNT @simply_pathology

https://instagram.com/simply_p....athology?igshid=1hwt

PLEASE DO SHARE WITH THOSE IN NEED!!

NEXT USMLE PLAB MBBS BDS AYUSH NEET-PG NEXT-2022

UNDERGRADUATE & POST GRADUATE LEARNING!!

THANKS FOR YOUR SUPPORT!!

Making Such Videos Needs Lots Of Hard Work! My Videos Will Always Remain Free For Every Medical Student From Around The Globe! If You Feel Like Making A Donation Here is The Link

https://www.paypal.me/simplypathology
https://www.patreon.com/simplypathology

If You Don't Feel Like Just Ignore And Enjoy The Videos.
Thank You
REGARDS
DR JIBRAN AHMED

Considerations for CPX-351 in Acute Myeloid Leukemia
Considerations for CPX-351 in Acute Myeloid Leukemia administrator 2 Views • 2 years ago

Expert panelists Eunice Wang, MD; Harry Erba, MD, PhD; Alexander E. Perl, MD; and Jorge E. Cortes, MD, identify important considerations when treating acute myeloid leukemia with CPX-351, such as its toxicity profile and patient stratification.
The Chronic Leukemias | Cancer in the Bone Marrow and The Blood Stream
The Chronic Leukemias | Cancer in the Bone Marrow and The Blood Stream administrator 3 Views • 2 years ago

😍🖼Animated Mnemonics (Picmonic): https://www.picmonic.com/viphookup/medicosis/

- With Picmonic, get your life back by studying less and remembering more. Medical and Nursing students say that Picmonic is the most comprehensive and effective way to bridge learning and test prep...
Disclaimer: I use affiliate links....

►👨‍🏫💊Antibiotics Lectures: https://www.medicosisperfectio....nalis.com/products/c ... Check out my brand new "Electrolytes" course at https://www.medicosisperfectio....nalis.com/products/c and use the PROMO code: ELECTROLYTES50 to get a 50% discount. ► Right Now! You can get access to all my hand-written hematology video notes (the notes that I use on my videos) on Patreon...There is a direct link through which you can view, download, print and enjoy! Go to https://www.patreon.com/medicosis To get access to leukemia videos right now, before anyone else...Go to my patreon page www.patreon.com/medicosis If you like my videos, please consider leaving a tip at https://www.paypal.me/perfectionalis/
► Visit my website: https://www.medicosisperfectionalis.com/ My Favorite Productivity App: https://airtable.com/invite/r/2zH40fus/ 📱Save on your mobile phone bill: http://fbuy.me/q6bMj 🏦 Qbank (TrueLearn): https://truelearn.referralrock.com/l/MEDICOSIS/

Acute Promyelocytic Leukema (aPML) | t(15;17) | AML_M3 | ATRA
Acute Promyelocytic Leukema (aPML) | t(15;17) | AML_M3 | ATRA administrator 3 Views • 2 years ago

😍🖼Animated Mnemonics (Picmonic): https://www.picmonic.com/viphookup/medicosis/

Disclaimer: I use affiliate links....

►👨‍🏫💊Antibiotics Lectures: https://www.medicosisperfectio....nalis.com/products/c ... Course a t(15;17) translocation...Treated with ATRA (tretinoin).


If you like my videos, please consider leaving a tip at https://www.paypal.me/perfectionalis/


► Visit my website: https://www.medicosisperfectionalis.com/

My Favorite Productivity App: https://airtable.com/invite/r/2zH40fus/

📱Save on your mobile phone bill: http://fbuy.me/q6bMj 🏦 Qbank (TrueLearn): https://truelearn.referralrock.com/l/MEDICOSIS/

Progress in acute myeloid leukemia treatment – collaborating to develop targeted therapies
Progress in acute myeloid leukemia treatment – collaborating to develop targeted therapies administrator 4 Views • 2 years ago

Wolfgang Hiddemann, MD, PhD, from the University Hospital Grosshadern, Ludwig-Maximilians-University (LMU), Munich, Germany discusses progress in acute myeloid leukemia (AML) treatment at the International Symposium on Acute Leukemias (ISAL) 2017 in Munich, Germany. He highlights the progress that has been made over the past decades, comparing his personal experience in the 1970s, when almost all acute myeloid leukemia patients died, to the current situation, where around 40% of patient are cured in the younger patient group up to the age of 60. Prof. Hiddemann describes promising developments, such as the deeper insight we now have into disease biology, the ability to define molecular changes impacting on the clinical course, and the possibility of using these molecular changes to direct treatment. He argues that while there has been no breakthrough yet in identifying specific targets for improving acute myeloid leukemia treatments, the search for the best targets requires a collaboration between clinicians to enroll patients in clinical trials, basic researchers to choosing pathways to target, and the pharmaceutical industry. Prof. Hiddemann points out that the aim is to improve acute myeloid leukemia patient outcomes, and not to increase the amount of drugs that can be sold.
ASH Video: Vincerx Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models
ASH Video: Vincerx Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models administrator 2 Views • 2 years ago

ASH Video Presentation: Vincerx Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models
Why can patients have either a high or low white blood cell count at diagnosis?
Why can patients have either a high or low white blood cell count at diagnosis? administrator 7 Views • 2 years ago

Get exclusive access to our latest content as soon as it's filmed for free at https://www.healthtree.org/aml/university
HealthTree University for acute myeloid leukemia offers a comprehensive online curriculum with lessons, quizzes and course discussion. Create a free account today to track your progress, earn points to win prizes, and stay up to date on the latest advancements in treating AML!

Topics covered include: AML basics, allogeneic stem cell transplant, AML genetics, relapsed and refractory AML and much more. We've partnered with AML experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree University.

Stay up to date on the latest AML news through our newsletter! https://healthtree.org/aml/community/newsletter

Follow HealthTree:
Twitter: https://www.twitter.com/HealthTreeAML
Facebook: https://www.facebook.com/HealthTreeForAML
Instagram: https://www.instagram.com/healthtreeforaml

Showing 1 out of 2